REPL (Replimune Group, Inc.) Market Value to Book Value Ratio

The available price action for Replimune Group, Inc. (REPL) reflects the dynamics of a company developing immune-based oncology drugs. The business faces uncertainty regarding test results and the risk of equity dilution, with the metric standing at 9.82. The share price depends on scientific breakthroughs rather than economic cycles. Operations are supplemented by strict compliance with bio-waste disposal standards and chemical controls.

Replimune Inc. (REPL): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for Replimune Group Inc (REPL)

- price and consensus price forecast:

Price Chart Replimune Group, Inc.|REPL - Price Target Chart

- market capitalization data:

Market Value Replimune Corp|REPL - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Replimune|REPL - Accounting Capitalization|Market Capitalization to Book Value Ratio replimune.com|REPL - Cumulative Company Assets

- debt and liquidity data:

Debt to Equity Replimune Group, Inc.|REPL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Replimune Corp|REPL - Company Debts|Debt to Book Capitalization Ratio Replimune Corp

Fundamental valuation:Replimune Group, Inc.

This indicator measures the market value premium over net assets, reflecting investor expectations regarding the future value of the business relative to its current tangible asset base. Analyzing the market-to-book ratio chart for Replimune Group, Inc. (REPL) reveals how ownership of a cGMP facility and an R&D center creates a fundamental basis that ensures the company's operational stability amid a high market valuation of its innovative potential.

Competitor analysis